期刊
JOURNAL OF ASTHMA
卷 59, 期 11, 页码 2201-2217出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/02770903.2021.2008431
关键词
Therapy; treatment; management; control; quality of life
资金
- GlaxoSmithKline (GSK) [213095]
The study found that patients with severe asthma receiving mepolizumab treatment in real-world settings consistently demonstrate clinically relevant benefits, including reduced exacerbation rates, decreased oral corticosteroid doses, improved lung function, asthma control and health-related quality of life.
Objective The efficacy and safety of mepolizumab in patients with severe eosinophilic asthma in randomized controlled trials is well established. Following approval of mepolizumab as add-on therapy for severe eosinophilic asthma in multiple regions worldwide, it is now important to determine its impact in real-world settings in which patients are not subject to stringent eligibility criteria. This systematic literature review assessed published evidence of clinical outcomes, safety, and healthcare resource use among patients with severe asthma receiving mepolizumab in real-world settings. Data sources Searches were conducted in Embase, MEDLINE, and MEDLINE In-Process via Ovid. Study selections Eligible studies were observational, and enrolled >= 10 patients with asthma who received mepolizumab 100 mg subcutaneously. Data extracted included annualized exacerbation rate, mean daily oral corticosteroid (OCS) dose, proportion of patients using OCS, several measures of lung function, patient-reported asthma control and health-related quality of life (HRQoL), safety, and economic burden. Results Twenty-three articles (22 unique studies; 2,040 patients with severe asthma on mepolizumab) were identified. Mepolizumab use was associated with a reduction in annualized exacerbation rates (requiring OCS) of 54-97% (p < 0.05 in all studies), reduced mean/median daily OCS doses, and OCS discontinuation during follow-up (27-84% of patients). Improvements in lung function, asthma control, and HRQoL were also observed. The most commonly reported adverse events included headache and arthralgia; discontinuation of mepolizumab due to adverse events occurred in 0-10.6% of patients. Conclusion Findings show that patients with severe asthma consistently demonstrate clinically relevant benefits with mepolizumab treatment in a real-world setting. Supplemental data for this article is available online at at www.tandfonline.com/ijas .
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据